Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.

According to Alnylam, the option gives Sylentis the chance to develop an siRNA-based treatment for an undisclosed glaucoma target using Alnylam's IP.

Upon execution of the option, Alnylam would receive upfront and milestone payments, and royalties on product sales. Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.